Copy Link Print Information

Lebrikizumab

(Synonyms: TNX-650; MILR1444A; RG3637)
1 Cited Publications
Customer Review

Based on 1 publication(s) in Google Scholar

Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases.

For research use only. We do not sell to patients.

  • Purity: 99.90%
  • CAS No.: 953400-68-5
  • Molecular Weight:145.318 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Lebrikizumab
  • Experimental Validation Results for Lebrikizumab
  • Experimental Validation Results for Lebrikizumab
  • Lebrikizumab Chemical Structure
    Lebrikizumab Chemical Structure
CAS No.: 953400-68-5
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Lebrikizumab

More

All Interleukin Related Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG4 kappa

  • 1/16

    Lebrikizumab (HY-P99025) neutralizes Recombinant Human IL-13 (HY-P70568) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.9529 μg/mL in the presence of 10 ng/mL Recombinant Human IL-13.

  • 1/16

    Loaded Lebrikizumab on AHC2 biosensor, can bind IL-13 Protein, Human (HEK293, His, HY-P70568) with an affinity constant of 7.283E-10 M as determined in BLI assay.

  • Lebrikizumab Chemical Structure
    1/16
  • Lebrikizumab
  • Lebrikizumab (HY-P99025) neutralizes Recombinant Human IL-13 (HY-P70568) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.9529 μg/mL in the presence of 10 ng/mL Recombinant Human IL-13.
  • Loaded Lebrikizumab on AHC2 biosensor, can bind IL-13 Protein, Human (HEK293, His, HY-P70568) with an affinity constant of 7.283E-10 M as determined in BLI assay.